MONTREAL, QUEBEC--(Marketwire - April 14, 2008) - MethylGene Inc. (TSX: MYG) today disclosed clinical biomarker data for its isoform-selective histone deacetylase (HDAC) inhibitor, MGCD0103, as well as preclinical efficacy data when MGCD0103 is administered in combination with taxanes. The data were presented in two poster sessions and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
